| Name | Title | Contact Details |
|---|
Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Smith-Sterling Dental Laboratories is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.